Welcome to our dedicated page for NuVasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on NuVasive stock.
NuVasive, Inc. (NASDAQ: NUVA) is a leader in spine technology innovation, dedicated to transforming spine surgery with minimally disruptive, procedurally integrated solutions. Headquartered in San Diego, NuVasive aims to advance surgical care and improve patient outcomes through its extensive product portfolio and global reach.
The company’s core offerings include surgical access instruments, spinal implants, fixation systems, biologics, and software for surgical planning. NuVasive also provides navigation and imaging solutions, magnetically adjustable implant systems for both spine and orthopedics, and intraoperative neuromonitoring technology and services. With an emphasis on speed of innovation, NuVasive continually develops new products to meet the evolving needs of spine surgeons, hospitals, and patients.
NuVasive has shown robust financial performance, with over $1 billion in net sales and operations in more than 50 countries. The company's recent achievements include a 2.4% increase in total net sales for the second quarter of 2023, reaching $317.8 million. This growth is driven by the adoption of new products and higher procedural volumes in the U.S.
The company is on the path to combining with Globus Medical, which is anticipated to drive further value creation for shareholders and expand its impact on improving patient lives globally. This merger is expected to enhance NuVasive's ability to deliver innovative and clinically proven outcomes.
NuVasive also emphasizes corporate social responsibility through initiatives like the NuVasive Spine Foundation®, which provides life-changing spinal surgery to disadvantaged communities, and other patient-to-patient support programs.
For more information, visit www.nuvasive.com.
NuVasive, Inc. (NASDAQ: NUVA) has launched Modulus® ALIF, a 3D-printed porous titanium implant designed for anterior lumbar interbody fusion. This innovative technology aims to enhance osseointegration and improve surgical outcomes. The implant features a proprietary design, zero-step locking mechanism, and versatile instrumentation for various patient anatomies. Positive feedback from surgeons highlights its potential in achieving better fusion results. NuVasive will showcase Modulus ALIF at industry events, reinforcing its commitment to spine surgery innovation.
NuVasive (NASDAQ: NUVA) announced it will release its second quarter 2021 earnings results on July 28, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss financial performance. The call can be accessed via dial-in or through a live webcast on the company's Investor Relations page. NuVasive, a leader in spine technology, focuses on minimally disruptive surgical solutions and has over $1 billion in net sales and approximately 2,700 employees globally.
NuVasive (NASDAQ: NUVA) announced CE Mark approval for its Pulse® platform, marking a significant step in commercialization. This approval allows clinical evaluations in multiple European countries ahead of a global launch planned for later this summer. The Pulse platform integrates various surgical technologies to enhance safety and efficiency in spine surgery. NuVasive aims to leverage this technology in all spine procedures, with demonstrations scheduled at industry events in July 2021.
NuVasive, Inc. (NASDAQ: NUVA) has appointed Daniel J. Wolterman as the independent chair of its Board of Directors, effective immediately. This change follows the retirement of Gregory T. Lucier on May 18, 2021. Wolterman, who joined the Board in July 2015 and has held the position of lead independent director since May 2020, brings nearly 40 years of healthcare experience, including 14 years as CEO of Memorial Hermann Health System. His leadership is expected to support NuVasive's strategy to transform spine surgery and enhance shareholder value.
NuVasive (NASDAQ: NUVA) announced the appointment of Juliet C. Cunningham as vice president of Investor Relations, effective immediately. With over 25 years of experience, Cunningham previously held the same role at Illumina and has extensive experience in investor relations at companies like QUALCOMM. Her role will focus on enhancing the investor relations program and engaging with the investment community. CFO Matt Harbaugh expressed confidence in her ability to drive the company’s long-term strategy as NuVasive aims to transform spine surgery through innovative solutions.
NuVasive reported a 4.4% increase in net sales for Q1 2021, totaling $271.2 million, with a GAAP operating margin of 4.5% and a non-GAAP operating margin of 13.0%. The company experienced a GAAP loss of $7.5 million or $0.15 per share compared to a profit of $5.3 million a year earlier. International sales grew in the low double digits, aided by a recovery in elective surgeries post-COVID-19. The acquisition of Simplify Medical received positive feedback, contributing to strong innovation in spine technology.
NuVasive (NASDAQ: NUVA), a leader in spine technology innovation, announced its participation in two upcoming virtual investor conferences. The Bank of America Securities 2021 Virtual Healthcare Conference is scheduled for May 13, 2021, at 11:00 a.m. ET, while the 2021 Canaccord Genuity Virtual Musculoskeletal Conference will take place on May 20, 2021, at 11:30 a.m. ET. Investors can access the live webcast via the Company’s website, with a replay available for 30 days post-event. NuVasive generates over $1 billion in net sales and operates globally, serving spine surgeons and hospitals.
NuVasive, Inc. (NASDAQ: NUVA) announced it will release its first quarter 2021 earnings on May 5, 2021, post-market. A conference call scheduled for the same day at 4:30 p.m. ET will discuss financial results. Interested parties can access the call via dial-in or live webcast on NuVasive's Investor Relations page. The call will be available for replay until June 5, 2021. NuVasive specializes in innovative spine technology, achieving over $1 billion in net sales, and operates in over 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) announced FDA approval for its Simplify® Cervical Artificial Disc for two-level cervical total disc replacement (cTDR). This landmark approval enhances the growing NuVasive C360 portfolio and signifies strong market potential due to its clinical superiority over traditional anterior cervical discectomy and fusion (ACDF) procedures, with nearly 10% higher overall success rates noted. The Simplify Disc’s innovative design promotes improved patient outcomes and is set to be showcased at the upcoming ISASS Annual Conference.
NuVasive, Inc. (NASDAQ: NUVA) announced the retirement of Gregory T. Lucier from its Board of Directors, effective May 18, 2021. Lucier, who has been with the company since December 2013 and served as CEO from May 2015 to November 2018, played a crucial role in driving NuVasive’s growth to over $1 billion in net sales. His leadership fostered innovation and expansion in spine technology. The company acknowledges Lucier's contributions while expressing confidence in its current leadership to continue advancing its mission and strategies.
FAQ
What is the market cap of NuVasive (NUVA)?
What does NuVasive, Inc. specialize in?
Where is NuVasive headquartered?
What are some of NuVasive's core products?
How did NuVasive perform in the second quarter of 2023?
Is NuVasive involved in any mergers or acquisitions?
How does NuVasive contribute to social responsibility?
What is the mission of NuVasive, Inc.?
In how many countries does NuVasive operate?
What recent financial milestone has NuVasive achieved?
Where can I find more information about NuVasive?
